Akebia Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 167
- Market Cap
- $319.6M
- Website
- http://www.akebia.com
- Introduction
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded...
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 210
- Registration Number
- NCT01906489
42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 93
- Registration Number
- NCT01381094
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
- First Posted Date
- 2010-11-08
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT01235936
© Copyright 2024. All Rights Reserved by MedPath